Table II.
Clinicopathological features of patients with perihilar bile duct carcinoma according to the expression levels of MSLN and CA125.
| MSLN expression | CA125 expression | Co-expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameter | High level (n=21) | Low level (n=10) | P-value | High level (n=18) | Low level (n=13) | P-value | Positive (n=15) | Negative (n=16) | P-value |
| Histological classification | |||||||||
| Grade 1/2 | 15 | 10 | 0.074 | 13 | 12 | 0.176 | 10 | 15 | 0.072 |
| Grade 3 | 6 | 0 | 5 | 1 | 5 | 1 | |||
| Type | |||||||||
| Papillary-expanding | 1 | 1 | NC | 0 | 2 | NC | 0 | 2 | NC |
| Papillary-infiltrating | 5 | 3 | 6 | 2 | 4 | 4 | |||
| Nodular-expanding | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Nodular-infiltrating | 9 | 4 | 7 | 6 | 7 | 6 | |||
| Flat-expanding | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Flat-infiltrating | 6 | 2 | 5 | 3 | 4 | 4 | |||
| pT stage UICC | |||||||||
| pT1-2 | 9 | 7 | 0.152 | 8 | 8 | 0.347 | 6 | 10 | 0.210 |
| pT3-4 | 12 | 3 | 10 | 5 | 9 | 6 | |||
| pN stage UICC | |||||||||
| pN0 | 5 | 6 | 0.060 | 3 | 8 | 0.014 | 1 | 10 | 0.002 |
| pN1-2 | 16 | 4 | 15 | 5 | 14 | 6 | |||
| pStage UICC | |||||||||
| pI–II | 3 | 5 | 0.048 | 2 | 6 | 0.037 | 0 | 8 | 0.002 |
| pIII–IV | 18 | 5 | 16 | 7 | 15 | 8 | |||
| Lymphatic permeation | |||||||||
| Positive | 20 | 9 | 0.548 | 18 | 11 | 0.168 | 15 | 14 | 0.258 |
| Negative | 1 | 1 | 0 | 2 | 0 | 2 | |||
| Blood vessel permeation | |||||||||
| Positive | 19 | 9 | 0.704 | 18 | 10 | 0.064 | 15 | 13 | 0.125 |
| Negative | 2 | 1 | 0 | 3 | 0 | 3 | |||
| Neural invasion | |||||||||
| Positive | 19 | 9 | 0.704 | 18 | 10 | 0.064 | 15 | 13 | 0.125 |
| Negative | 2 | 1 | 0 | 3 | 0 | 3 | |||
| Residual tumor | |||||||||
| R0 | 9 | 3 | 0.390 | 6 | 6 | 0.470 | 6 | 6 | 0.886 |
| R1 | 12 | 7 | 12 | 7 | 9 | 10 | |||
| Recurrence | |||||||||
| Yes | 6 | 5 | 0.221 | 14 | 6 | 0.076 | 11 | 9 | 0.269 |
| No | 15 | 5 | 4 | 7 | 4 | 7 | |||
Data analyzed via Fisher's exact test (for parameters with expected values of <5 in >20% of cells) or χ2 test. MSLN, mesothelin; CA125, cancer antigen 125; UICC, Union for International Cancer Control; pT stage, pathological tumor stage; pN stage, pathological lymph node stage; NC, not calculated.